Silence Therapeutics plc

SLNNASDAQHealthcare● Active

$6.09

$-0.08(-1.30%)

Market Cap$287654743

P/E Ratio—

52W High$8.4

52W Low$4.19

Avg Volume331K

Open$6.24

Beta1.44

Overview

Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

Silence Therapeutics plc (SLN) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · SLN · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-4.32Earnings history

PE Ratio (TTM)—PE Ratio deep dive

Revenue (TTM)921490.00Full revenue history

Dividend YieldNo DividendDividend history

Shares Outstanding47.2MShares outstanding history

Next EarningsAug 6, 2026Est.Earnings history

Explore Silence Therapeutics plc Data

Market Cap$289.5M

Analyst Forecast$57 · Buy

DividendsNo Dividend

Revenue$559000-98.71%

EarningsEPS $-1.89+20.25%

PE Ratio—

Financial Snapshot

Full Financials

FY 2025Revenue$559000.00▼ 98.71% YoY

202320242025

FY 2025Net Income-$88.6M▼ 95.57% YoY

202320242025

FY 2025EPS$-1.89▲ +20.25% YoY

202320242025

TTM:Revenue: $921490.00Net Income: -$85.2MEPS: $-4.32View income statement →

Analyst Ratings & Price Target

Full Forecast

Buy5 analysts

Strong Buy

Buy

Hold

Sell

Strong Sell

12-Month Price Target

$49.00Low

$6.09Current

$57.00Avg Target835.96% upside

$67.00High

Total: 5 · Buy rate: 80.0%

The SLN analyst consensus is Buy, based on ratings from 5 Wall Street analysts over the past 3 months. The average 12-month price target is $57.00, representing +835.96% upside from the current price of $6.09.

Competitors & Peers

#TickerCompanyPriceChangeMkt Cap

SLN

Silence Therapeutics plc

$6.09-1.30%$287.7M #2

ACIU

AC Immune S.A.

$2.22-2.89%$225.4M #3

ALDX

Aldeyra Therapeutics, Inc.

$1.78+7.98%$107.1M #4

AMRN

Amarin Corporation plc

$14.14+2.51%$292.5M #5

ANRO

Alto Neuroscience, Inc.

$18.17+0.52%$637.7M #6

CAPR

Capricor Therapeutics, Inc.

$26.62-0.90%$1.2B

Stock Performance

Full History

1D-0.65%

1W-3.62%

1M-12.05%

3M-1.61%

YTD+0.82%

1Y+15.44%

5Y-77.09%

About Silence Therapeutics plc

CEOIain Gladstone Ross

IPO DateSep 8, 2020

Employees116

CountryGB

Websitesilence-therapeutics.com

Silence Therapeutics plc a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic ind…

Biotechnology HealthcareNASDAQADRGB

About Stock Overview & Key Data

Silence Therapeutics plc (SLN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Sep 8, 2020. As of the latest trading session, SLN stock price is $6.09, with a market capitalization of $289.5M. The stock has returned +15.44% over the past 12 months and +0.82% year-to-date.

According to 5 Wall Street analysts, the consensus rating for Silence Therapeutics plc stock is Buy, with an average 12-month price target of $57.00. In fiscal year 2025, Silence Therapeutics plc reported revenue of $559000.00 and net income of -$88.6M. For detailed data — including Silence Therapeutics plc revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Silence Therapeutics plc (SLN) stock price is $6.09. The stock is traded on NASDAQ under the ticker symbol SLN. The 52-week range is $4.19 – $8.40.

SLN stock priceSLN quote todaylive ticker

Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice